FDA Approves Gilead’s Once-Daily Bixlenvo HIV Treatment
The U.S. Food and Drug Administration has approved Bixlenvo, a once-daily HIV treatment developed by Gilead Sciences for adults whose virus is already suppressed. The single-tablet regimen is intended primarily for patients who cannot use existing one-pill therapies because of drug resistance, side effects, interactions with other medicines, or other treatment complications.
Bixlenvo combines bictegravir, an ingredient in Gilead’s Biktarvy, with lenacapavir, a capsid inhibitor that attacks HIV through a different mechanism. Gilead says the combination offers a simplified option for an estimated 5% or more of Americans living with HIV who currently require complex regimens. It may also be considered by patients who are stable on other therapies but want an alternative.
The approval was supported by two Phase 3 studies involving adults with suppressed HIV. Participants included people switching from Biktarvy and patients taking multiple daily medicines. In the ARTISTRY-1 trial, participants had a median age of 60 and previously took between two and 11 pills each day. At 48 weeks, Bixlenvo maintained viral suppression at rates comparable with earlier regimens. The most commonly reported side effects were headache, nausea, and diarrhea, and investigators identified no new safety concerns.
Gilead set Bixlenvo’s list price at $4,595 for a 30-day supply before discounts and rebates, similar to other daily single-tablet HIV treatments. The company says assistance may be available for eligible uninsured and privately insured patients.
For some people with long treatment histories, reducing several medications to one daily tablet could make dosing easier. Gilead emphasized that Bixlenvo is not intended to replace Biktarvy, but to broaden patient choice. The drug also forms part of the company’s wider strategy to develop lenacapavir-based daily, weekly, and long-acting HIV treatments.
HIV remains incurable, but effective antiretroviral therapy can suppress the virus and help patients manage the condition over the long term.